Considering that hyperactive KIT mutations are highly prevalent in CBF-AML (about 35% of cases)[6] and that CCDC26 focal amplification (CCDC26amp) is found more frequently in CBF-AML than in non CBF-AML [22, 23], these findings could reveal a new lesion associated with aberrant tyrosine kinase pathway activation in CBF-AML patients. The gene discussed is CCDC26; the disease is acute myeloid leukemia.